Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | -7.17% | -5.91% | +52.68% |
Mar. 13 | Cresco Labs Swings to Profit in Q4, Revenue Drops; Up 10.4% | MT |
Mar. 13 | Cresco Labs Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+52.68% | 780M | - | ||
+33.46% | 701B | C+ | ||
+26.24% | 571B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 319B | C+ | ||
+0.74% | 210B | B+ | ||
+2.95% | 210B | B- | ||
-6.05% | 201B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Cresco Labs Inc.
- Stock Cresco Labs Inc. - OTC Markets
- Ratings Cresco Labs Inc.